1. 2 >70 300 ˜100 3 >2 000 >380 000 4 Paediatric regulation.

Slides:



Advertisements
Similar presentations
6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Advertisements

EPAA Annual conference November Regulatory acceptance of alternative approaches for pharmaceuticals Jean-Marc Vidal Safety & Efficacy of Human Medicines.
Background information
Registration in Europe Current situation and future outlook Thomas K ü rner, M.D. Nippon Boehringer Ingelheim Co., Ltd.
“5th anniversary Paediatric Regulation” PDCO Achievements
FP7 Projects in Rare Anaemias: DEEP - Deferiprone Evaluation in Paediatrics Adriana Ceci DEEP Scientific Coordinator, on behalf of DEEP Consortium.
The Paediatric Regulation
Daniel J. Isaacman, m.D., FAAP
Regulatory Requirements for Orphan Drugs Delivery Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Professor of Pharmaceutics KLE University, Belgaum, India
Interactions between CHMP and PDCO; reflections from a CHMP perspective Tomas Salmonson vice-chair, CHMP.
REGULATION (EC) No 1901/2006 of 12 December 2006 on medicinal products for paediatric use Article 45 and more… Christer Backman CMD(h) Sweden.
The State of Pediatric Clinical Trials in Europe A Regulatory Overview by Virinder Nohria, MD, PhD Presented at ASENT Annual Meeting Dinner Symposium Washington.
The role of EMEA in Orphan Drug Development Thomas Lönngren, EMEA Stockholm, 15 February 2005.
Collaboration between FDA and EMA
Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.
An introduction to the EU and its legislation. Member States currently 15 –Austria- Ireland –Belgium- Luxembourg –Denmark- Netherlands –Finland- Portugal.
1 The European Paediatric Initiative Agnès Saint Raymond, MD Scientific Advice and Orphan Drugs The European Medicines Evaluation Agency.
The Advanced Therapy Medicinal Products Regulation from the European Medicines Agency (EMEA)'s perspective Nathalie Rampal Olmedo EMEA – Directorate –
Unlicensed Medicines in Paediatrics Is there a problem ? Scottish Neonatal and Paediatric Pharmacist Group National Paediatric Pre- Registration Pharmacist.
Patents in the pharmaceutical industry
Registration in lebanon
Pharma.be The Initiative to Promote Clinical Trials in Belgium Key Performance Indicators: Impact on Clinical Research of European Legislation Square –
Subsequent Entry Biologics (SEBs) – Canada Presentation to AIPLA Biotechnology Committee January 25, 2012 Daphne C. Lainson
Data protection and extension of patent rights TRIPS requirements & TRIPS-plus provisions Carlos Correa.
Victoria Junction, Waterfront
REGULATION OF CLINICAL TRIALS IN PAEDIATRIC POPULATION DIFFERENCES BETWEEN TRIALS IN ADULTS AND CHILDREN presented by GYURASICS, ÁGNES MD PhD National.
NIHR Medicines for Children Research Network (MCRN) Prof Ian Wong Chair, MCRN Pharmacy & Pharmacology Clinical Study Group Associate Director of London.
Stefan Franzén Introduction to clinical trials.
Accessibility of medicinal products before marketing authorisation : The French experience C. Bélorgey Division on Evaluation of medicinal products of.
Data exclusivity, patents and registration of medicines Karin Timmermans TWN Regional Workshop Kuala Lumpur on bilateral trade agreements Aug
Dr Peter Arlett European Commission Orphan medicines: DG Enterprise and Industry perspective ICORD February 2005.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Patents and Medicines: How the system has discouraged innovation and reduced patient access to benefits of knowledge GREG PERRY Director General, EGA World.
Human Subjects Research Cynthia Edmonds Director, Office of Research Support Committees.
Regulating Herbal Medicines in Europe Heribert PITTNER Federal Ministry of Health and Women, Vienna, Austria 8th European Health Forum Gastein 7 October.
1 10 th Annual European Scientific and Regulatory Affairs Conference New Pharmaceutical legislation: One year experience… 21 November 2006 Bernard Lemoine.
Paediatric Worksharing CMDh participation Work-sharing in Art 45 and 46 procedures Experiences in Art 29 procedures Presidency meeting 29 September 2011.
Federal agency for medicines and health products EC REGULATION 1901/2006 ON MEDICINAL PRODUCTS FOR PAEDIATRIC USE AND HOMEOPATHIC MEDICINAL PRODUCTS Marie-Anne.
Europe & USA: Interactions on Pediatric Clinical Trials
Drugs for children Irja Lutsar Tallinn 2007.
Biotechnology Chemical Pharmaceutical Customer Partnership
Food and Drug Administration Amendments Act of 2007 Reauthorization of Pediatric Initiatives Lisa L. Mathis, M.D. Pediatric and Maternal Health Staff Office.
An agency of the European Union Orphan Medicine Designation and development in Rare Diseases Segundo Mariz Scientific Administrator Orphan Medicines Office.
February 2, 2004 Pediatric Drug Development: A Decade of Progress: Susan K. Cummins, MD, MPH Medical Team Leader Division of Pediatric Drug Development.
'Hot topics' ESSENTIAL MEDICINES FOR CHILDREN Suzanne Hill September 2006.
Initiatives Drive Pediatric Drug Development January 30, 2002.
Transatlantic Administrative Simplification Workshop European Preparatory Roundtable Suzette Kox EGA Senior Director Scientific Affairs.
An agency of the European Union Agnes Saint Raymond, Human Medicines Special Areas Human Medicines Development and Evaluation Unit How effective is the.
“EMA policy on publication of Clinical Data” 27/11/2014SFdS - Journée Annuelle du groupe Biopharmacie & Santé.
1 Bolar Provisions in Europe Robert Watson Chartered Patent Attorney European Patent Attorney AIPLA, February 2006.
Condition vs. indication Chairs & Introduction: Nathalie Rampal, European Medicines Agency (EMA); Genevieve Michaux, Covington & Burling, Belgium Rapporteur:
Developing Medicines For Paediatric Populations EU Perspective Didem Crosby Senior Regulatory Affairs Manager F. Hoffmann–La Roche Ltd
ICORD 2006 Kerstin Westermark Md, PhD, Assoc. prof. COMP Chairperson.
Researching Drug Studies across European Public Assessment Reports & FDA Approval Packages Linda Bowen, MS, RAC Director RI, US Region sanofi-aventis Insert.
Bundesinstitut für Arzneimittel und Medizinprodukte Joint ISCTM/ASENT Meeting, Feb. 2012, Washington, DC Challenges in Paediatric Drug and Device Development.
Off-label Use.
Paediatric Medicine: The Paediatric Investigation Plan
A capacity building programme for patient representatives
PAEDIATRIC REGULATION
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Biotechnology Chemical Pharmaceutical Customer Partnership
SPCs and the unitary patent package
Concepts of Paediatric Investigation Plans (PIP)
OECD Principles of GLP and Test Guidelines
Scope of Supplementary Protection Certificates (SPCs)
ICTMS Communicating Trial Results to participants
Suzanne M. Sensabaugh, MS, MBA
Pediatric Therapeutics Still working to get it right for kids
An introduction to EMA’s support for medicines development
Presentation transcript:

1

2 > ˜100

3 >2 000 >

4 Paediatric regulation

5 Key objectives of the new EU Paediatric Regulation –To improve the health of the children of Europe by: increasing high quality research for medicinal products for children promoting the development and authorisation of such medicines at the EU level improving the information on medicines designed for children –While avoiding unnecessary studies in children and not delaying the authorisation of medicines for adults

6 EU Paediatric Regulation 3 Pilars Paediatric Investigation Plan (PIP) Reward (incentives) for studies conducted Paediatric Committee (PDCO) at the EMEA

7 PIP Includes timing of planned studies for all the paediatric population subsets applicable to 1.Pharmaceutical development (paediatric forms) 2.Pre-clinical studies (such as juvenile toxicity) 3.Clinical studies in children Subsets of population to be considered (neonates, infants, children, adolescents)

8 EU Paediatric Regulation Key elements Mandatory paediatric development for new products according to a PIP agreed upon by the PDCO (possible deferrals or waivers) Mandatory submission of paediatric data when filing new applications unless waiver or deferral approved by the PDCO New Marketing Authorisation Procedure for off-patent products (PUMA)

9 Incentives Incentives for new medicinal products and line extensions of patented medicinal products: Reward for studies conducted: 6-month extension of the patent or the supplementary protection certificate (SPC) Covers new indications, new pharmaceutical forms and new route of administration For orphan medicines, 2-year additional market exclusivity (10+2)

10 Incentives Incentives for off-patent medicines specifically developed for children New type of Marketing Authorisation (PUMA) Paediatric Use Marketing Authorisation Covers only the paediatric indication(s) and formulation(s) Enabling 10-year (8+2) data protection

11

12 COMPOSITION: 5 CHMP members + 1 members per Member State not yet represented + 6 members from families & HCP associations Each member has an alternate PDCO

13 Early

14 PIP applications EMEA received after 12 months of activities (by submission deadline ) PIP applications* 356 corresponding to Number of indications covered in the requests for PIPs or waivers: 596 including full waivers for the paediatric development for the whole indication 58 * ‘Application’ covers one or more indication(s)

15 Facilitate Research

16 Rapporteur

17 Peer Reviewer

18

19 Thank you